ITEMS IN AFP WITH KEYWORD:
Conjugated estrogens/bazedoxifene is effective for the treatment of menopausal symptoms and may be better tolerated than conjugated estrogens/medroxyprogesterone. It will maintain bone mineral density in the lumbar spine and hip, but its effect on fractures is not known. Cardiovascular safety beyond two years is not known.
Sep 1, 2014 Issue
ACOG Releases Clinical Guidelines on Management of Menopausal Symptoms [Practice Guidelines]
The American College of Obstetricians and Gynecologists (ACOG) has provided recommendations for the treatment of vasomotor and vaginal symptoms related to menopause.
Mar 15, 2013 Issue
Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: Recommendation Statement [U.S. Preventive Services Task Force]
The U.S. Preventive Services Task Force (USPSTF) recommends against the use of combined estrogen and progestin for the prevention of chronic conditions in postmenopausal women.
Mar 15, 2013 Issue
Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions [Putting Prevention into Practice]
Case Study: A 59-year-old healthy, postmenopausal woman presents for a routine health maintenance visit. She has an intact uterus and no history of skeletal fractures. She asks if menopausal hormone therapy would help prevent chronic illness, specifically stroke and dementia.
Nov 1, 2012 Issue
AACE Releases Guidelines for Menopausal Hormone Therapy [Practice Guidelines]
Menopause is diagnosed in women who have not had menses for one year. The American Association of Clinical Endocrinologists (AACE) convened a task force to review available evidence on therapies for menopausal symptoms. The task force's guidelines include recommendations for prescribing menopausal h...
Feb 1, 2012 Issue
Exercise for Treatment of the Vasomotor Symptoms of Menopause [Cochrane for Clinicians]
Although menopausal women who exercise are less likely to report vasomotor symptoms than those who do not, there is insufficient evidence that counseling women to exercise is more effective than no treatment or hormone therapy for vasomotor symptoms of menopause.
Jul 1, 2011 Issue
Hormone Therapy for Postmenopausal Women with Urinary Incontinence [FPIN's Clinical Inquiries]
Postmenopausal women should not receive oral hormone therapy for treatment of urinary incontinence.
The results of recent large clinical trials have led physicians and patients to question the safety of menopausal hormone therapy. In the past, physicians prescribed hormone therapy in an attempt to improve overall health and prevent cardiac disease. Hormone therapy appears to increase the risk of b...
Soybeans contain all of the essential amino acids necessary for human nutrition and have been grown and harvested for thousands of years. Populations with diets high in soy protein and low in animal protein have lower risks of prostate and breast cancers than other populations. Increasing dietary wh...
Menopause is the permanent cessation of menstruation resulting from the loss of ovarian and follicular activity. It usually occurs when women reach their early 50s. Vasomotor symptoms and vaginal dryness are frequently reported during menopause. Estrogen is the most effective treatment for managemen...